Petros Pharmaceuticals, Inc. Operating Income Loss

Quick Answer

Petros Pharmaceuticals, Inc. reported Operating Income Loss of -$17.68 million for the year ending 2024.

  • Petros Pharmaceuticals, Inc. showed a decrease of -29.8% in Operating Income Loss from 2023 to 2024.
  • This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
  • XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Operating Income Loss has declined by 2.3%.
  • Historical annual values: Fiscal year 2024: -$17.68 million | Fiscal year 2023: -$13.62 million | Fiscal year 2022: -$19.92 million | Fiscal year 2021: -$18.05 million | Fiscal year 2020: -$17.28 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: